In Alzheimer's disease, lipid alterations point towards peroxisomal dysfunctions. Indeed, a cortical accumulation of saturated very long chain fatty acids (VLCFAs: C22:0, C24:0, C26:0), substrates for peroxisomal β-oxidation, has been found in Alzheimer patients. This study was realized to investigate the effects of VLCFAs at the mitochondrial level since mitochondrial dysfunctions play crucial roles in neurodegeneration. On human neuronal SK-NB-E cells treated with C22:0, C24:0, or C26:0 (0.1-20 μM; 48 h), an inhibition of cell growth and mitochondrial dysfunctions were observed by cell counting with trypan blue, MTT assay, and measurement of mitochondrial transmembrane potential (Δψ m ) with DiOC 6 (3). A stimulation of oxidative stress was observed with DHE and MitoSOX used to quantify superoxide anion production on whole cells and at the mitochondrial level, respectively. With C24:0 and C26:0, by Western blotting, lower levels of mitochondrial complexes III and IV were detected. After staining with MitoTracker and by transmission electron microscopy used to study mitochondrial topography, mass and morphology, major changes were detected in VLCFAs treated-cells: modification of the cytoplasmic distribution of mitochondria, presence of large mitochondria, enhancement of the mitochondrial mass. Thus, VLCFAs can be potential risk factors contributing to neurodegeneration by inducing neuronal damages via mitochondrial dysfunctions.
Introduction
Alzheimer's disease (AD; OMIM #104300) is a neurodegenerative disorder. This is a clinicopathological entity regarded as progressive dementia, which includes episodic memory impairment and the involvement of other cognitive domains or skills that are associated with the reduction of daily activities and behavioral changes [1, 2] . AD is characterized by the presence of two aberrant structures in patients' brains: senile plaques and neurofibrillary tangles [3] . Senile plaques are composed of β-amyloid peptides, particular fragments of the amyloid peptide precursor protein (APP) [4] , whereas the main component of neurofibrillary tangles is the cytoskeleton protein interacting with the microtubules known as the tau protein, in its hyperphosphorylated form [5, 6] . Currently, only very few treatments, which minimally impact the disease, are available [1] . Therefore, for a better understanding of the physiopathology of AD, there is a real need to identify the molecules capable of favoring the development of this disease, to determine their biological activities and the associated metabolic pathways in order to discover new therapeutic targets. Some investigations support a linkage between lipid metabolism and AD [7] [8] [9] . The most widely studied risk factors are the three common variants of the human apolipoprotein E (apoE) protein, known as E2, E3, and E4. The gene variants underlying 2 Oxidative Medicine and Cellular Longevity these protein isoforms, known as ε2, ε3, and ε4 are allelic forms of the APOE gene, resulting from different haplotypes at the APOE locus (19q13.31) [10] . As many carriers of the APOE risk allele (ε4) live into their 90 s, the existence of other late-onset AD genetic and/or environmental risk factors have yet to be identified [11] . Some evidence has accumulated that cholesterol oxide derivatives, also called oxysterols, which are 27 carbon derivatives of cholesterol containing additional oxygen atoms on the steroid's nucleus or on the side chain, can be used as markers of brain atrophy in patients with various neurodegenerative diseases [12, 13] . The accumulation of oxysterols in the body may be due to dietary consumption (dried egg products, powdered milk, cheeses, and dried animal products); they can also be formed enzymatically, mostly by cytochromes P450 (CYPs) [14] , and also nonenzymatically by reaction with oxygen [15] . Oxysterols have various biological activities (induction of cell death, activation of inflammation, and/or oxidative processes) and are therefore assumed to play major roles in various pathologies including AD [13, 16] . Potential roles of 7-ketocholesterol and 7β-hydroxycholesterol have been suggested [17, 18] , and it was found that reduction of the plasmatic level of 24S-hydroxycholesterol correlated with the severity of dementia or the degree of brain atrophy [19] . 24S-hydroxycholesterol formed by a specific cholesterol 24-hydroxylase (CYP46A1), a cytochrome P450 enzyme expressed in neurons, is considered as a marker of metabolically active neurons [20] , and under in vitro conditions, it is an efficient inhibitor of β-amyloid peptide formation, a major component of senile plaques [21, 22] . Therefore, conversion of cholesterol into 24S-hydroxycholesterol in the brain is of critical importance for central cholesterol homeostasis and 24S-hydroxycholesterol could play important roles in the development of AD [23, 24] . Moreover, regarding the decline of peroxisomal function with age [25, 26] , peroxisomal dysfunctions associated with aging might favor neurodegenerative diseases, including AD [27, 28] . In agreement with this hypothesis, some lipid alterations observed in AD, concerning docosahexaenoic acid (DHA, C22:6 n-3), very long chain fatty acids (VLCFAs: C22:0, C24:0 and C26:0), and plasmalogens also point towards peroxisomal dysfunctions given that the β-oxidation or the synthesis of these lipids occurs, at least in part, in the peroxisome [29, 30] . Recently, lipid analyses of cortical regions from patients with AD revealed accumulation of VLCFAs (C22:0, C24:0, and C26:0), three substrates for peroxisomal β-oxidation, in patients with stages V and VI pathology compared with those modestly affected (stages I and II) based on the neuropathological Braak staging for AD [31] . Conversely, the level of plasmalogens, which need intact peroxisomes for their biosynthesis, was decreased in severely affected tissues, in agreement with a peroxisomal dysfunction. In addition, the peroxisomal volume density was increased in some neurons in the gyrus frontalis at advanced AD stages [31] . Based on these later observations, it is tempting to speculate that the accumulation of C22:0, C24:0, and C26:0 in the cortex of patients with AD could contribute to neuron dysfunctions. Indeed, these fatty acids are known to induce various types of cellular damages, in vitro and in vivo, especially at the mitochondrial and lysosomal level, and to trigger oxidative stress and cell death in the cells of the central nervous system [32] [33] [34] [35] .
In order to evaluate the ability of C22:0, C24:0, and C26:0 to induce neuronal damages, human neuronal cells (SK-NB-E) were cultured in the absence or in the presence of these fatty acids at various concentrations (0.1, 1, 5, 10, and/or 20 μM) for 48 h. We focused on the effects of these fatty acids at the mitochondrial level since mitochondria are assumed to play important roles in the development of AD [36] [37] [38] , and we observed that C22:0, C24:0, and C26:0 were able to induce morphological and functional modifications of this organelle.
Materials and Methods

Cells and Cell Treatments.
Human neuronal cells (SK-NB-E) were seeded at 200,000 cells per well in 12-well microplates containing 1 mL of culture medium constituted by Dulbecco's Modified Eagle Medium with L-gutamine (DMEM) (Lonza) supplemented with 10% (v/v) heat-inactivated fetal bovine serum (FBS) (Pan Biotech) and 1% antibiotics (100 U/mL penicillin, 100 mg/mL streptomycin) (Pan Biotech). Cells were incubated at 37
• C in a humidified atmosphere containing 5% CO 2 and passaged twice a week. At each passage, SK-NB-E cells were trypsinized with a (0.05% trypsin-0.02% EDTA) solution (Pan Biotech).
Docosanoic acid (C22:0), tetracosanoic acid (C24:0), and hexacosanoic acid (C26:0) (Sigma-Aldrich) were solubilized in α-cyclodextrin (Sigma-Aldrich) as previously described [39] . The final maximum concentration of α-cyclodextrin (vehicle) in the culture medium was 1 mg/mL [33] .
The conditions of treatment with very long chain fatty acids (VLCFAs) (C22:0, C24:0, or C26:0) were the following: after plating SK-NB-E cells for 24 h, the cells were further treated for 48 h with various VLCFA concentrations (0.1, 1, 5, 10, and/or 20 μM) in HAM's F-10 medium (Pan Biotech). The concentrations of VLCFAs were chosen according to measurements made in similar experimental conditions on the plasma of healthy subjects (C22:0, C24:0, or C26:0: less than 1 μM), of patients with X-ALD (C22:0, C24:0, or C26:0: from 1 to 5 μM) (used as positive controls) [34, 40] , and of patients with AD. Our preliminary data concern 15 Alzheimer patients from the department of Neurology (University Hospital, Monastir, Tunisia): C22:0 (mean, 4.2 μM; range, 0.8-8.4 μM) and C24:0 (mean, 4.9 μM; range, 0.8-10.6 μM).
Colorimetric MTT Assay.
The MTT assay was carried out as previously described [41] on SK-NB-E cells plated in 12-well flat-bottom culture plates after 48 h of treatment with C22:0, C24:0, or C26:0 (0.1, 1, 5, 10, and 20 μM). The MTT assay was used to evaluate the effects of C22:0, C24:0, and C26:0 on cell proliferation and/or viability. MTT salt is reduced to formazan in the metabolic active cells by dehydrogenase to form NADH and NADPH [42] . The plates were read at 570 nm with a microplate reader. (3) , mitochondrial depolarization is indicated by a decrease in green fluorescence collected through a 520/10-nm band pass filter. DiOC 6 (3) was used at a 40 nM [43] . Flow cytometric analyses were performed on a Galaxy flow cytometer (Partec). Ten thousand cells were acquired for each sample. Data were analyzed with Flomax software (Partec) or FlowJo software (Tree Star Inc.).
Flow Cytometric Measurement of the Whole Intracellular
Production of Superoxide Anion with Dihydroethidium. The whole intracellular production of superoxide anion (O 2
•− ) was detected with dihydroethidium (DHE; Invitrogen/Life Technologies), which is a nonfluorescent compound that can diffuse through cell membranes, rapidly oxidized in hydroethidine (HE) under the action of O 2
•− [44] . DHE was initially prepared at 10 mM in dimethyl sulfoxide (DMSO) and used at a 2 μM final concentration on cell samples of 1 × 10 6 cells/mL of HAM'S F10 medium. Cells were incubated for 15 min at 37
• C before flow cytometric analysis. The fluorescent signals were collected through a 580 ± 20 nm band pass filter on a logarithmic scale of four decades of log on a GALAXY flow cytometer (Partec). For each sample, 10,000 cells were acquired. Data were analyzed with Flomax software (Partec).
Flow Cytometric Measurement of Mitochondrial Superoxide Anions with
MitoSOX. The mitochondrial production of superoxide anion (O 2
•− ) was detected with MitoSOX (Invitrogen/Life Technologies). MitoSOX Red reagent is a livecell permeant and is rapidly and selectively targeted to the mitochondria [45] . Once in the mitochondria, MitoSOX Red reagent is oxidized by superoxide and exhibits orange/red fluorescence (λEx = 510 nm; λEm = 580 nm). The oxidation product becomes highly fluorescent upon binding to nucleic acids. MitoSOX was initially prepared at 5 mM in PBS and used at 5 μM on cell samples of 1 × 10 6 cells/mL of PBS. Cells were incubated for 15 min at 37
• C before flow cytometry analysis. The fluorescent signals were collected through a 580 ± 20-nm band pass filter on a Galaxy flow cytometer (Partec). For each sample, 10,000 cells were acquired. Data were analyzed with Flomax software (Partec).
Labeling of Mitochondria with MitoTracker for the Microscopical Evaluation of Mitochondrial Distribution and Flow
Cytometric Evaluation of Mitochondrial Mass. The mitochondrial mass and the cellular distribution of mitochondria were evaluated after staining with MitoTracker Red (Invitrogen) [45] .
To evaluate mitochondrial distribution, SK-NB-E cells were cultured on glass coverslips, and after 48 h of culture in the absence or in the presence of fatty acids, they were stained with MitoTracker Red at 1 μM (15 min, 37
• C). After labeling, the coverslips were washed in PBS, mounted in Dako fluorescent mounting medium (Dako), and stored in the dark at 4
• C until observation under blue light. Observations were made under an Axioskop fluorescent microscope (Zeiss) using green excitation, and digitalized images were obtained with an Axiocam Zeiss camera.
To determine the mitochondrial mass, SK-NB-E cells were cultured in 12-well microplates, and after 48 h of culture in the absence or in the presence of fatty acids, they were stained with MitoTracker Red (1 μM, 15 min, 37
• C). After trypsinization, the cells were washed and resuspended in PBS and immediately analyzed using flow cytometry. The fluorescent signals were collected through a 580 ± 20 nm band pass filter on a Galaxy flow cytometer (Partec). For each sample, 10,000 cells were acquired and the data were analyzed with Flomax software (Partec).
Western Blot Analysis of Mitochondrial
Proteins. SK-NB-E cells were treated with C26:0, C24:0, and C22:0 at 5 and 10 μM for 24 and 48 h. After treatment, cells were trypsinized and incubated with Ripa lysis buffer (0.1% (w/v) SDS, 1% (w/v) NP40, 0.5% (w/v) Na-desoxycholate, 150 mM NaCl, 2 mM EDTA, and 50 mM TrisHCl pH 8) containing a mixture of protease and phosphatase inhibitors (NaF 50 mM, Protease Inhibitor Cocktail Tablets (Roche)). After 30 min incubation at 4
• C in the lysis buffer, the cell debris were eliminated by centrifugation (20 min, 10,000 g), and the supernatant was collected. The protein concentrations were measured using bicinchoninic acid reagent (Sigma) [46] . Fifty micrograms of protein per slot were diluted in loading buffer (125 mmol/L Tris/HCl, pH 6.8, 10% (w/v) mercaptoethanol, 4.6% (w/v) SDS, 20% (v/v) glycerol, and 0.003% (w/v) Bromophenol blue), separated by SDS-PAGE and transferred to nitrocellulose membrane. After blocking nonspecific binding sites overnight by 5% nonfat milk in TPBS (PBS, 0.1% Tween20), the membranes were incubated for 1 h at room temperature with the anti- the membranes were incubated with horseradish peroxidaseconjugated secondary antibody (Santa Cruz Biotechnology) at a 1 : 5000 dilution (TPBS with 5% nonfat milk) for 1 h at room temperature and washed three times in TPBS for 10 min. Autoradiography of the immunoblots was performed using an enhanced chemoluminescence detection kit (Santa Cruz Biotechnology) and they were quantified with Image J Software. The results were expressed as a fold change to untreated SK-NB-E cells. Actin was used as a loading control. The monoclonal antibodies in the cocktail were chosen because they are against subunits that are labile when the corresponding complex is not assembled. Moreover, the combination is readily resolved in SDS-PAGE when the appropriate gel conditions are used.
Transmission Electron Microscopy.
Transmission electron microscopy is a valuable tool to evaluate the morphological changes occurring under the action of various physical or chemical agents [47] . It was used to visualize the potential ultrastructural modifications induced especially at the mitochondrial level by fatty acids (C22:0, C24:0, and C26:0 used at 10 μM; 24 h) and α-cyclodextrin (1 mg/mL for 24 h, used as vehicle to dissolve fatty acids) on SK-NB-E cells, and was conducted as previously described [48] .
Statistical Analysis.
Statistical analyses were performed using WinSTAT software (Microsoft). The Mann-Whitney U test was used to compare the different groups, and data were considered to be statistically different at a P value of 0.05 or less. The effects of C22:0, C24:0, and C26:0 on oxidative stress, mainly on superoxide anion production, were investigated at concentrations inducing modifications on cell growth and on mitochondrial transmembrane potential. To this end, SK-NB-E cells were incubated with C22:0, C24:0, and C26:0 (5-20 μM) for 48 h and the production on superoxide anions on whole cells and at the mitochondrial level was determined after staining with DHE and MitoSOX, respectively. After staining with DHE, whatever the fatty acid considered, a marked increase of cells overproducing superoxide anions (HE-positive cells) was observed at 10 and 20 μM (Figure 5(a) ). With MitoSOX, whatever the fatty acid considered, our data show an increase of superoxide anion production at the mitochondrial level at 10 and 20 μM with C22:0 and C24:0, and at 20 μM with C26:0 ( Figure 5(b) ). As the increase of MitoSOX positive cells was lower than those of HE-positive cells, these data suggest that the mitochondria contribute in part to the increase of superoxide anion production on whole cells. (Figure 6(a) ) associated with a quantitative densitometry analysis (Figure 6(b) ). In these conditions, when compared to untreated cells (control), similar values of the different complexes were observed in α-cyclodextrin (vehicle)-treated cells, and under treatment with C22:0. However, some changes were observed especially under treatment with C24:0 and C26:0, mainly on Complexes III and IV, which are proton pumps contributing to the proton gradient by an asymmetric absorption/release of protons. Thus, C24:0 (5 μM) reduced the level of Complex III subunit core 2, whereas C24:0 (10 μM) increased it, and the opposite was shown for C26:0. However, both C24:0 and C26:0 (5 and 10 μM) reduced the level of Complex IV subunit II ( Figure  5(b) ). (Figure 7(a) ). It is noteworthy that these mitochondrial changes revealed by fluorescence microscopic observations were associated with an enhancement of the mitochondrial mass measured by flow cytometry (Figure 7(b) ). In agreement with the data obtained with MitoTracker Red, the observations made using transmission electron microscopy also showed substantial mitochondrial changes. Whereas the distribution (Figures 8(a) 
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Discussion
Brain aging leading to cognitive decline, including AD, is an incompletely understood process that different hypotheses attempt to explain. Currently, the agents contributing to brain aging-associated dysfunctions are not well known; nor are the possible underlying mechanisms involved in cognitive decline [38] . The increased accumulation of VLCFAs (C22:0, C24:0, and C26:0) found in cortical regions from patients with AD [31] , the important roles played by various lipids, including different types of fatty acids, in the physiopathology of AD [7] , and the mitochondrial changes occurring with advancing age [51, 52] led us to attempt to characterize the effects of C22:0, C24:0, and C26:0 at the mitochondrial level on human neuronal cells (SK-NB-E). We observed that these different fatty acids induced important morphological and functional changes at the mitochondrial level.
Since mitochondria are unlikely to play a significant role in cellular MTT reduction, the MTT assay, which gives information on mitochondrial activity and cell growth, was used to evaluate the sensitivity of SK-NB-E cells to C22:0, C24:0, and C26:0. With the MTT assay, the lower ability of SK-NB-E cells to reduce MTT to formazan blue in the presence of these fatty acids revealed the cytotoxic effects of these compounds in concentrations 5 μM and higher, which was similar to those previously described on glial cells [34] . Compared to untreated and vehicle-treated cells, the higher MTT value observed under treatment with C24:0 (0.1 μM) suggests mitochondrial hyperactivity (previously reported with cytotoxic compounds [53] ), which could take place to counteract early mitochondrial dysfunctions. We cannot exclude that a similar effect occurs with C22:0 and C26:0 used at 0.1 μM before or after 48 h of treatment. Moreover, in agreement with data obtained on glial cells (oligodendrocytes, astrocytes), C22:0 and VLCFAs (C24:0, C26:0) also inhibit cell growth in a dose-dependent manner and favor cell detachment, as suggested by the presence of an increased number of clusters of round cells detected under treatment with these fatty acids [34] . The neurotoxic effects of C22:0, C24:0, and C26:0, via alterations of mitochondrial activity suggested by the MTT assay, were confirmed with the use of DiOC 6 (3), which is a reliable fluorescent probe used to measure the mitochondrial transmembrane potential (ΔΨ m ) [54] . With this probe, the higher percentages of cells with depolarized mitochondria found under treatment with C22:0, C24:0, and C26:0 demonstrate that there is a significant impact of these fatty acids on mitochondrial activity, which can contribute to triggering cell death [34, 48] . This mitochondrial disturbance was also observed on rat C6 glioma cells, murine oligodendrocytes 158 N [34] , normal fibroblasts, and fibroblasts of X-ALD patients [55] as well as oligodendrocytes and astrocytes of rat brain [33] treated with C24:0 or C26:0 used at 20 μM and higher, indicating that a decrease of ΔΨ m is common to neural cells and fibroblasts and provides evidence that mitochondrialdependent cellular dysfunctions are triggered by elevated VLCFA concentrations. Therefore, when the effects of C22:0, C24:0, and C26:0 were evaluated with the MTT assay by cell counting in the presence of trypan blue or after staining with DiOC 6 (3), since similar activities of these fatty acids were found on glial cells and neural cells, these different data suggest that these compounds may have dramatic consequences on various brain functions and that they can trigger neurodegeneration.
Currently, some investigations support that oxidative damage can favor brain senescence and neurodegeneration via mitochondrial dysfunctions [36, 37, 52] and that oxidative-stress-mediated energetic failure may be at the core of multifactorial neurodegenerative diseases [56] . There is also some evidence that accumulation of VLCFAs in different tissues and biological fluids simultaneously stimulates oxidative stress leading to lipid peroxidation and decreases the antioxidant defenses [57] [58] [59] [60] . Moreover, VLCFAs are known to favor overproduction of reactive oxygen species (ROS) and reactive nitrogen species (RNS) on various types of cells, including neuronal cells [35, 55] , and VLCFAinduced oxidative damage could further compromise energy metabolism [61] . It was therefore useful to specify the ability Oxidative Medicine and Cellular Longevity As it has been postulated that oxidative stress in mitochondria can reduce their activities and contribute to decreasing the mitochondrial transmembrane potential (ΔΨ m ) [52, 61] , the overproduction of superoxide anions at the mitochondrial level was investigated with the fluorescent probe MitoSOX [45] . In these conditions, our data show that mitochondrial dysfunctions were associated with an increase of superoxide anion production at the mitochondrial level.
However, as the increase of MitoSOX-positive cells was lower than those of HE-positive cells, we can assume that C22:0, C24:0, and C26:0 have other targets than mitochondria to stimulate superoxide anion production. It is therefore tempting to speculate that extramitochondrial sources of ROS production, especially superoxide anion, could be activated by C22:0, C24:0, and C26:0 and could in turn contribute to inducing mitochondrial damage [62] . Indeed, the accumulation of VLCFAs in X-ALD lymphoblasts has been described to increase the level of NADPH oxidase gp91 PHOX observed in total cell homogenate and membrane fractions of those cells [63, 64] . Therefore, C24:0 and C26:0 might favor the activation of NADPH oxidase activity, leading to an overproduction of ROS, which might further contribute to modifying mitochondrial activity and to triggering cell death [65] . Since it has been demonstrated that excess C26:0 generates ROS, which results in oxidation (both with C24:0 and C26:0 (5 and 10 μM)) observed on SK-NB-E cells was in agreement with observations on fibroblast primary cultures of PEX5-deficient mice where a reduction of the core I subunit of Complex III and subunit I of Complex IV was found [68] . It remains to be determined whether the different effects between C24:0 and C26:0 on Complex III subunit Core 2 are characteristic of these fatty acids or whether they depend not only on their concentrations, but also on the time of treatment considered. In addition to these functional mitochondrial dysfunctions, some topographical, quantitative, and morphological modifications of the mitochondria were also observed under treatment of SK-NB-E cells with C22:0, C24:0, and C26:0. Thus, using MitoTracker Red, which identifies the cytoplasmic distribution of mitochondria by fluorescence microscopy [45] , important changes were found under treatment with C22:0, C24:0, and C26:0. In contrast to the fluorescent dots often observed in control and α-cyclodextrintreated cells, a more diffuse and irregular staining pattern was detected in the presence of C22:0, C24:0, and C26:0. Moreover, with flow cytometry the higher fluorescence intensity of MitoTracker Red observed under treatment with C22:0, C24:0, and C26:0, compared to control and α-cyclodextrintreated cells, favors the hypothesis of an increase of the mitochondrial mass, recently reported with the use of this fluorochrome on cells submitted to chemical or physical stresses [69, 70] , which could correspond to either a higher number of mitochondria and/or the presence of mitochondria of larger sizes. Interestingly, these two possibilities are supported by the observations from transmission electron microscopy. Since fusion and fission of mitochondria are strictly controlled in neurons, malfunction in this process triggered by VLCFAs may contribute to activating neuronal death [48, 71] . In addition, as described on cardiac myocytes in stress conditions [72] , the biogenesis of mitochondria under treatment with C22:0, C24:0, and C26:0 could occur to compensate the loss of mitochondrial activity and to maintain the stability of mitochondrial metabolism. Moreover, in agreement with this hypothesis, on eicosapentaenoic acid-treated rat glioma C6 cells, it has been suggested that enhancement of mitochondrial biogenesis through enhanced PGC1-α and Tfam transcriptional activities may provide partial protection against cytotoxicity [73] .
Altogether, our data indicate that VLCFAs (C22:0, C24:0, and C26:0) could constitute potential risk factors in AD. They could favor neurodegeneration by inducing neuronal damages via their ability to induce mitochondrial dysfunctions. Therefore, as C22:0, C24:0, and C26:0 have been identified in the brain of patients with AD, they could contribute to the development of this pathology, and the mitochondria may constitute a rational target for therapeutic intervention [74] . Therefore, the ability to counteract the associated mitochondrial dysfunctions might help identify new therapeutic targets and develop efficient treatments in AD.
